touchPODCAST

Understanding alopecia areata: Current perspectives and emerging therapies for a complex disease

touchIN CONVERSATION for touchIMMUNOLOGY

Listen to two expert dermatologists, Dr Maryanne Senna and Dr Anna Waśkiel-Burnat, discuss current understanding of alopecia areata, including the burden associated with the disease, its pathophysiology, and the potential role of emerging therapies in improving patient outcomes. 

The discussion is stimulated by questions posed by healthcare professionals involved in the management of alopecia areata. 

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
www.touchimmunology.com 

Advancing the management of MDS and AML: Novel immune-based approaches

touchEXPERT OPINIONS for touchONCOLOGY 

Listen to three experts describe the role of immune dysregulation in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), and summarize the rationale and available data for emerging immune-based therapeutic strategies. In a short panel discussion, they consider the possible impact these therapies may have on future clinical practice.

The experts

• Prof. Dr. med. Uwe Platzbecker — University Hospital Leipzig, Leipzig, Germany
• Prof. Agnieszka Wierzbowska — Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland
• Prof. Valeria Santini — University of Florence, Florence, Italy

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: touchONCOLOGY

Experts in cytomegalovirus in solid organ transplants discuss management strategies and emerging therapeutic options

touchEXPERT OPINIONS for touchRESPIRATORY

Listen to three experts in cytomegalovirus (CMV) to learn about the unmet needs of solid organ transplant recipients susceptible to CMV infection. Topics covered will include management challenges in solid organ transplant recipients with CMV, the evolving antiviral options for refractory and resistant CMV, and best practice for the management of refractory/resistant CMV in these patients.

The experts

• Dr Camille Kotton – Massachusetts General Hospital, Boston, MA, USA
• Dr Raymund Razonable – Mayo Clinic, Rochester, MN, USA
• Dr Genovefa Papanicolaou – Memorial Sloan Kettering Cancer Center, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Takeda. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchrespiratoryime.org/eo-on-cmv-in-solid-organ-transplant-recipients/

Experts in cytomegalovirus in solid organ transplants discuss management strategies and emerging therapeutic options

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES

Listen to three experts in cytomegalovirus (CMV) to learn about the unmet needs of solid organ transplant recipients susceptible to CMV infection. Topics covered will include management challenges in solid organ transplant recipients with CMV, the evolving antiviral options for refractory and resistant CMV, and best practice for the management of refractory/resistant CMV in these patients.

The experts

• Dr Camille Kotton – Massachusetts General Hospital, Boston, MA, USA
• Dr Raymund Razonable – Mayo Clinic, Rochester, MN, USA
• Dr Genovefa Papanicolaou – Memorial Sloan Kettering Cancer Center, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Takeda. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchinfectiousdiseasesime.org/eo-on-cmv-in-solid-organ-transplant-recipients/

What’s new for eosinophilic esophagitis? A case-based discussion of patient care

touchEXPERT OPINIONS for touchRESPIRATORY

Listen to three experts in eosinophilic oesophagitis (EoE) to learn about the aetiology, pathophysiology and clinical manifestations of EoE, as well as the practical aspects of its diagnosis and management in children and adults based on clinical case studies.

The experts

• Dr Stuart Carr – Snö Asthma and Allergy, Abu Dhabi, UAE
• Dr Mário Vieira – Hospital Pequeno Príncipe, Curitiba, PR, Brazil
• Prof. Arjan Bredenoord – Amsterdam University Medical Center, Amsterdam, Netherlands
  
  

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchRESPIRATORY

What’s new for eosinophilic esophagitis? A case-based discussion of patient care

touchEXPERT OPINIONS for touchIMMUNOLOGY

Listen to three experts in eosinophilic oesophagitis (EoE) to learn about the aetiology, pathophysiology and clinical manifestations of EoE, as well as the practical aspects of its diagnosis and management in children and adults based on clinical case studies.

The experts

• Dr Stuart Carr – Snö Asthma and Allergy, Abu Dhabi, UAE
• Dr Mário Vieira – Hospital Pequeno Príncipe, Curitiba, PR, Brazil
• Prof. Arjan Bredenoord – Amsterdam University Medical Center, Amsterdam, Netherlands
  

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchIMMUNOLOGY

Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022

touchCONGRESS for touchONCOLOGY

Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel). 

OVERVIEW

• Data review with Dr Oliva (0:00)
• Expert interviews with Prof. Heuser, Dr Ofran and Dr Oliva, answering the questions below

INTERVIEW QUESTIONS

1. Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS? (30:08)
2. What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML? (35:47)
3. To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important? (42:06)
4. Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML? (49:55)

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/MDS-AML-EHA2022-touchcongress/

Advances in the first-line treatment of ES-SCLC: From clinical data to daily practice

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of leading lung cancer experts share their perspectives on recent advances in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and how they are changing clinical practice.

The experts

• Dr Marina Garassino - University of Chicago, Chicago, IL, USA
• Dr Louis Paz-Ares - Hospital Universitario 12 de Octubre, Complutense University and Ciberonc, Madrid, Spain
• DR Martin Edelman - Fox Chase Cancer Center, Philadelphia, PA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncology.com/ES-SCLC-first-line-treatment

Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?

touchTALKS for touchONCOLOGY

Listen to an esteemed lung cancer expert discuss KRAS mutations in solid tumours, particularly non-small cell lung cancer and colorectal cancer, and consider the role of direct KRAS-G12C inhibitors in targeting these mutations and potential strategies to overcome resistance.

The expert:

• Prof. Tony Mok, Chinese University of Hong Kong, Hong Kong

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/kras-g12c-inhibitors-for-solid-tumours/

 

Improving outcomes for patients with advanced renal cell carcinoma

touchIN CONVERSATION for touchONCOLOGY

Listen to Dr Cristina Suárez, a clinician in Spain with a specialist focus on genitourinary tumors, in conversation with Dr Toni Choueiri, a renal cell carcinoma (RCC) expert. They respond to questions submitted by the HCP audience and provide their expert insights on how emerging combination therapies in the first-line setting can improve outcomes for patients with advanced RCC.

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Exelixis, Inc., and Merck and Co., Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/in-conversation-improving-outcomes-advanced-rcc-role-of-emerging-combinations-first-line/